Fig. 4.

The hazard ratio receiver operating characteristic (hROC) quantifies the predictive performance of the biomarker. a For the subC-LP signature, the hazard ratios of aflibercept-treated patients versus baseline-treated patients in the relatively-resistant and sensitive populations, hR(R) (red) and hR(S) (blue) respectively, are plotted versus the fraction q of patients declared sensitive, all quantities being generated parametrically by sweeping the decision threshold ∆ξ_c left-to-right across Fig. 3. The horizontal dashed line labeled hR (all) denotes the aflibercept-to-control hazard ratio for all patients taken together (hR (all) = 0.486). The area A_bc between the red and blue curves is a global measure of the predictive performance of the signature. In this case A_bc = 0.3341. b Corresponding profile of P-values for hR(S) and hR(R). The vertical dashed line corresponds to decision threshold ∆ξ_c = − 0.815, for which hR(S) = 0.28, pR(S) = 9.2 × 10^− 6, hR(R) = 0.738 and pR(R) = 0.165